FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to phthisiology and infectious diseases, and may be used for treating the patients with drug-resistant tuberculosis and HIV infection. For this purpose, with underlying high-active antiretroviral therapy (HA ART), the patient's state is clinically assessed, and observing the deterioration, temperature rise, developing inflammatory process in the involved organs, prednisolone 0.5 mg/kg is administered once daily orally for 10-12 days. After termination of the therapeutic course, the clinical parameters are assessed; observing the normalisation thereof enables stating the presence of the inflammatory immune reconstitution syndrome in the patients with drug-resistant tuberculosis and HIV infection with underlying the HAART. The prednisolone therapy is continued up to 3 weeks. In the absence of a positive effect of the use of prednisolone, the developing disease is associated by the progression of drug-resistance of tuberculosis mycobacteria, and the prednisolone therapy is withdrawn herewith correcting the anti-tuberculosis therapeutic regimen by prescribing the second-line anti-tuberculosis preparations.
EFFECT: method ensured providing higher clinical effectiveness in the patients with drug-resistant tuberculosis and HIV infection by eliminating the inadequate intensive therapy receiving the second-line anti-tuberculosis preparations causing a risk of developing side effects.
2 ex
